ThemeTumor-type
specific Sessions

Session Title

DIPG (basic)

Presentation
No.

AbstractNo.

Lecture title

Speaker

DIPB-IS-01

IS-20

Molecular pathways and therapeutic opportunities in DIPG

Nada Jabado

DIPB-O-02

DIPG-05

Histone H3.3 K27M impairs Ser31 phosphorylation, resulting in chromosomal instability,
Charles Day
loss of cell cycle checkpoint control, and tumor formation

DIPB-O-03

DIPG-03

Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma

DIPB-P-04

DIPG-13

Targeting hypoxia and mitochondria with repurposed metabolic drugs as an approach toHan Shenradiosensitization for Diffuse Intrinsic Pontine Gliomas (DIPG)

DIPB-P-05

DIPG-22

Dissecting the oncogenic role of FOXR2 in diffuse intrinsic pontine glioma

DIPB-P-06

DIPG-27

DIPB-P-07

DIPG-31

DIPB-P-08

DIPG-63

DIPB-P-09

DIPG-73

DIPB-P-10

DIPG-58

DIPB-P-11

DIPG-14

DIPB-P-12

DIPG-15

DIPB-P-13

DIPG-16

DIPB-P-14

DIPG-21

DIPB-P-15

DIPG-53

DIPB-P-16

DIPG-29

DIPB-P-17

DIPG-51

DIPB-P-18

DIPG-62

DIPB-P-20

DIPG-43

DIPB-P-21

DIPG-54

DIPB-P-22

DIPG-59

DIPB-P-23

Rintaro Hashizume

Jessica Tsai

Targeting Facilitates Chromatin Transcription (FACT) as a novel strategy for Diffuse
Maria Tsoli
Intrinsic Pontine Glioma (DIPG) that enhances response to histone deacetylase(HDAC) inhibition
Molecular mechanisms and functional impact of aberrant splicing in diffuse midline
Ammar Naqvigliomas
Loss of the H4 lysine methyltransferase KMT5B drives invasion / migration by depleting
Ketty Kessler
H3K27me3 at loci otherwise retained in H3K27M mutant DIPG cells
Senescence associated secretory phenotype as a mechanism of resistance andSujatha Venkataraman
therapeutic vulnerability in BMI1 inhibitor treated DIPG
Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum of diffuse
David Castelmidline gliomas with PRC2 inhibition beyond H3-K27M mutation
Targeting Polo-Like Kinase 1 in combination with key oncogenic drivers in DIPG: fromBenjamin Rayner
single agent to combination strategies.
Polyamine pathway inhibition is a potent novel therapeutic strategy against Diffuse
Maria Tsoli
Intrinsic Pontine Glioma
Combination of arginine depletion and polyamine inhibition as an anticancer strategy forAaminah Khan
diffuse intrinsic pontine glioma (DIPG)
Induction of mitotic abnormalities and BMI-1 modulation to treat diffuse intrinsic pontine
Rachid Drissi
gliomaCharacterizing the role of PPM1D mutations in the pathogenesis of Diffuse Intrinsic
Prasidda Khadka
Pontine Gliomas (DIPGs)
Phosphatidylinositol-4,5-Bisphosphate 3-Kinase (PI3K) inhibition drives Protein Kinase
Ryan Duchatel
C Activation (PKC) in Diffuse Intrinsic Pontine Glioma (DIPG)Country
CanadaUSA
USA
Australia
USA
Australia
USAUKUSAFranceAustralia
Australia
Australia
USAUSA
Australia

Jennifer Ocasio Adorno

USARobyn Borsuk

USADavid Eisenstat

USALoris De CeccoItaly

Upregulation of prenatal pontine ID1 signaling in DIPG

Micah Harris

USA

DIPG-70

Disordered DNA methylation in DIPG underlies phenotypic plasticity

Michael Koldobskiy

USA

DIPB-P-24

DIPG-76

Histone H3 phosphorylation in H3K27M midline gliomas

Liang Zhang

USA

DIPB-P-25

DIPG-78

DIPB-P-26

DIPG-79

DIPB-P-27

DIPG-07

DIPB-P-28

DIPG-18

Identification of targetable pathway dependencies in Diffuse Intrinsic Pontine Glioma.

Sarah Parackal

CanadaDIPB-P-29

DIPG-32

Akt signaling drives resistance to ONC201 in Diffuse Intrinsic Pontine Glioma (DIPG)

Evangeline Jackson

Australia

DIPB-P-30

DIPG-34

Super elongation complex as a targetable dependency in H3K27M+ diffuse midline
gliomaNathan Dahl

USA

DIPB-P-31

DIPG-44

A gain of function Ezh2 mutation delays Diffuse Intrinsic Pontine Glioma progression

Swati Dhar

USA

DIPB-P-32

DIPG-47

Histone mutations enhance RAS mediated ERK5 growth signaling in diffuse midline
gliomasSameer Agnihotri

USA

DIPB-P-33

DIPG-60

Pilot study of circulating tumor cells in pediatric high grade brain tumors

Dristhi Ragoonanan

USADIPB-P-34

DIPG-08

Electronic sequencing provides optimized quantification of serial, multi-gene molecularresponse in the CSF of children with high-grade glioma

Andrea Franson

USA

DIPB-P-35

DIPG-12Targeting epigenetic modifiers to induce immune signaling in DIPG

Ashley Tetens

USA

DIPB-P-36

DIPG-39

Novel proteomic analysis reveals epigenetic therapeutic targets in pediatric glioma

Amanda Saratsis

USA

DIPB-P-37

DIPG-40

Targeting master regulator dependencies in diffuse intrinsic pontine glioma (DIPG)

Jovana PavisicUSADIPB-P-38

DIPG-41

Dissecting the mechanistic basis for ACVR1 and PIK3CA mutation co-occurrence indiffuse midline gliomas using genetically engineered mouse models

Jerome Fortin

CanadaDIPB-P-39

DIPG-57

Transcriptomic and proteomic analyses of DIPG response to ONC201

Sreepradha Sridharan

USA

DIPB-P-40

DIPG-68

Chen ShenUSA

DIPB-P-41

DIPG-71

Katherine Barnett

USA

DIPB-P-42

DIPG-83

Filip Michniewicz

Australia

DIPB-P-43

DIPG-50

Jacqueline Whitehouse

Australia

DIPB-P-44

DIPG-10

Nicholas Vitanza

USA

DIPB-P-45

DIPG-56

Marie-Anne Debily

France

DIPB-P-46

DIPG-19

Karen Tsui

New Zealand

ACVR1 mutations promote tumor growth in models of diffuse intrinsic pontine glioma
Preclinical evaluation of imipridone-based combination therapies in pediatric H3K27M
mutant diffuse intrinsic pontine glioma (DIPG)Can we reprogram diffuse intrinsic pontine glioma (DIPG)? Exploring the role ofdistalless/Dlx homeobox gene regulation of oligodendroglial progenitor cells (OPC) inthe developing vertebrate nervous system
A non-invasive prognostic circulating miRNAs signature in diffuse intrinsic pontinegliomas

Revertance of the H3K27M mutation rescues chromatin marks necessary for
Cody Nesvick
oncogenesis in diffuse midline glioma
H3K27M induces epigenetic and oncogenic changes that are partially reversed by small
Adam Green
molecule Aurora kinase B/C inhibition
High throughput drug screening identifies potential new therapies for Diffuse Intrinsic
Dannielle Upton
Pontine Gliomas (DIPGs)

Alpha-thalassemia X-linked mental retardation protein (ATRX) loss-of-function in amouse model of diffuse intrinsic pontine glioma
Selective HDAC inhibitor RG2833 induces DIPG cell death via downregulation of theNFĸB pathway
Using copper chelating agents to target receptor tyrosine kinase signalling in diffuse
intrinsic pontine glioma (DIPG)
A novel patient-derived mouse model of radiation-associated diffuse midline glioma
following medulloblastoma
Optimal HDAC inhibition in diffuse intrinsic pontine glioma
Exploration of tumor/stroma interactions in DIPG xenograft by species-specific RNAseq deconvolution indicates a role of microglia cell in DIPG development
Targeting ATM mutation in metastatic diffuse midline glioma – a case of sustained
response using PARP inhibitorUSAUSA
Australia